The most stringer barrier for the delivery of neurotherapeutics in-vivo is presented by the blood-brain barrier which limits the access of neurotherapeutics to the CNS effectively. Intranasal delivery of neurotherapeutics is one of the promising endeavors to surmount the blood-brain barrier, designated as direct nose to brain transport, by the passage of neurotherapeutics along the olfactory an...

2 Intrinsic Voltage Dynamics Govern the Diversity of Spontaneous Firing 3 Profiles in Basal Forebrain Non-cholinergic Neurons 4 5 6 Saak V. Ovsepian, Oliver J. Dolly and Laszlo Zaborszky 7 8 (1) Centre for Molecular and Behavioral Neuroscience, Rutgers, The State University of 9 New Jersey, 197 University Avenue, Newark, NJ 07102, USA; (2) International Centre 10 for Neurotherapeutics, Research...

In recent years there has been tremendous progress in advancing new treatments for neurologic and psychiatric illnesses. New agents have emerged for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, migraine, schizophrenia, bipolar illness, depression, and substance abuse disorders. Advances in understanding of basic pathophysiology and molecular biology o...

s from the Program of the Fourth Annual Meeting of the American Society for Experimental NeuroTherapeutics, Washington, DC, March 14-16, 2002. Setting Standards to Avoid Conflict of Interest in Clinical Trials